不可逆电穿孔增强 CAR-T 细胞对实体瘤的浸润与选择性癌细胞裂解
Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.
通过利用一种双用途转化策略——直接的癌细胞靶向细胞毒性和增强的 CAR-T 细胞浸润——sIRE 能够减轻肿瘤负荷，同时保持并增强 CAR-T 细胞功能。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
间皮瘤的免疫治疗：一个长期存在的治疗梦想的演变
英文原题：Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
查看英文原题
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胸膜间皮瘤（PM）是一种侵袭性且罕见的疾病，以极差的预后为特征。近二十年来，不可切除PM的全球标准治疗方案由铂类药物联合培美曲塞组成，总生存期约为12个月。随着免疫检查点抑制剂进入临床，PM的治疗格局近期发生了显著变化，免疫检查点抑制已被证明是改善PM患者生存的有效方法。本综述旨在全面概述目前正在研究中的针对晚期PM的最有前景的免疫治疗策略。
展开英文摘要原文
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months.
The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.
论文信息
- 作者
- Calabrò L、Bronte G、Grosso F、Cerbone L、Delmonte A、Nicolini F、Mazza M、Di Giacomo AM
- 第一作者单位
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy.Italy
- 通讯作者单位
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.Italy
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 38259475 · DOI 10.3389/fimmu.2023.1333661
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →